Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMNN | US
-0.07
-2.45%
Healthcare
Biotechnology
30/06/2024
24/04/2026
2.79
2.87
2.90
2.77
Imunon Inc. a clinical stage biotechnology company engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001 a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon Inc. in September 2022. Imunon Inc. was founded in 1982 and is based in Lawrenceville New Jersey.
View LessLow Debt to Asset (< 0.2)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
44.4%1 month
52.9%3 months
48.0%6 months
58.6%-
-
3.79
0.37
0.14
0.91
4.00
-
-19.62M
40.18M
40.18M
-
-
-
-
-143.19
1.64
3.01
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.47
Range1M
0.72
Range3M
1.37
Rel. volume
0.10
Price X volume
55.37K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | BTAI | Biotechnology | 1.06 | 43.19M | -3.64% | n/a | -139.46% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.12 | 40.68M | -4.27% | n/a | 3.91% |
| Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.28 | 39.88M | -2.29% | n/a | 4.22% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.1901 | 39.58M | -25.45% | n/a | 122.82% |
| Audentes Therapeutics Inc | BOLD | Biotechnology | 1.5 | 39.29M | -1.32% | n/a | 0.47% |
| Plus Therapeutics Inc | PSTV | Biotechnology | 6.6 | 38.92M | -9.34% | n/a | -45.04% |
| Alterity Therapeutics Limited | ATHE | Biotechnology | 4.41 | 38.56M | 0.92% | n/a | 1.15% |
| Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 0.813 | 35.53M | -5.48% | n/a | 35.26% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 3.3 | 33.65M | 4.76% | n/a | 2.12% |
| PDS Biotechnology Corporation | PDSB | Biotechnology | 0.9005 | 33.16M | -2.97% | n/a | 78.85% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.91 | 0.53 | Expensive |
| Ent. to Revenue | 4.00 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.79 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 47.96 | 72.80 | Lower Risk |
| Debt to Equity | 0.37 | -1.23 | Expensive |
| Debt to Assets | 0.14 | 0.25 | Cheaper |
| Market Cap | 40.18M | 3.66B | Emerging |